NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD - Announcements

Market Cap $5.206M Add to my watchlist

Healthcare Biotechnology

NeuroScientific Biopharmaceuticals Limited is an Australia-based company that is engaged... NeuroScientific Biopharmaceuticals Limited is an Australia-based company that is engaged in developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The Company's product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn), which have demonstrated similar therapeutic potential as EmtinB. EmtinB is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

NSB	NSB Completes PRE-IND Meeting with US FDA on EmtinB		11/06/24	412.17KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/24	1.31MB	Share
NSB	Notification of cessation of securities - NSB		08/04/24	12.77KB	Share
NSB	Appointment of Executive Director & FDA Pre-Ind Meeting	PRICE SENSITIVE	02/04/24	416.34KB	Share
NSB	NSB Receives A$2.2M Research & Development Tax Refund	PRICE SENSITIVE	20/03/24	410.52KB	Share
NSB	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/24	1.01MB	Share
NSB	Company Secretary Appointment/Resignation		06/02/24	115.12KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/24	311.96KB	Share
NSB	Notification of cessation of securities - NSB		15/01/24	21.59KB	Share
NSB	Expiry of Options		27/12/23	234.24KB	Share
NSB	Final Director's Interest Notice - Rennie		07/12/23	3.33KB	Share
NSB	Final Director's Interest Notice - Quantrill		05/12/23	3.43KB	Share
NSB	Initial Director's Interest Notice - Keating		05/12/23	228.43KB	Share
NSB	Changes to NSB Board		05/12/23	184.23KB	Share
NSB	Resignation of CEO	PRICE SENSITIVE	01/12/23	178.63KB	Share
NSB	Results of Meeting		30/11/23	285.36KB	Share
NSB	Chair's address to shareholders & AGM presentation		30/11/23	1.63MB	Share
NSB	Notice of Annual General Meeting - Withdrawal of Resolutions		27/11/23	157KB	Share
NSB	Initial Director's Interest Notice - Barlow		21/11/23	226.14KB	Share
NSB	Initial Director's Interest Notice - Ntoumenopoulos		21/11/23	227.89KB	Share
NSB	Notification of cessation of securities - NSB		21/11/23	21.66KB	Share
NSB	Addendum to Notice of Meeting		16/11/23	630.92KB	Share
NSB	Further information on changes to Board		14/11/23	158.29KB	Share
NSB	Changes to Board		13/11/23	169.11KB	Share
NSB	Investor Update Presentation		31/10/23	2.38MB	Share
NSB	Investor Update Webinar		30/10/23	150.57KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/10/23	357.42KB	Share
NSB	Notification regarding unquoted securities - NSB		24/10/23	28.78KB	Share
NSB	Proposed issue of securities - NSB		24/10/23	27.86KB	Share
NSB	Notice of Annual General Meeting/Proxy Form		24/10/23	412.54KB	Share
NSB	Proposed issue of securities - NSB		23/10/23	26.88KB	Share
NSB	Appointment of Director - Dr Linda Friedland		18/10/23	219.75KB	Share
NSB	Date of AGM & Closing Date for Director Nominations		28/09/23	165.12KB	Share
NSB	Appointment of CEO	PRICE SENSITIVE	31/08/23	154.04KB	Share
NSB	Appendix 4G		30/08/23	258.67KB	Share
NSB	Corporate Governance Statement		30/08/23	228.23KB	Share
NSB	2023 Annual Report and Appendix 4E	PRICE SENSITIVE	25/08/23	1.6MB	Share
NSB	Expiry of Performance Shares		01/08/23	153.59KB	Share
NSB	Notification of cessation of securities - NSB		01/08/23	21.82KB	Share
NSB	Issuance of Shares		01/08/23	159.19KB	Share
NSB	Application for quotation of securities - NSB		01/08/23	24.71KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/23	339.28KB	Share
NSB	Proposed issue of securities - NSB		27/07/23	24.67KB	Share
NSB	Change of Director's Interest Notice - Quantrill		06/07/23	4.45KB	Share
NSB	Change of Director's Interest Notice - Rennie		07/06/23	8.12KB	Share
NSB	Change of Director's Interest Notice - Uvarov		25/05/23	9.25KB	Share
NSB	Change of Director's Interest Notice - Rennie		25/05/23	8.11KB	Share
NSB	Change of Director's Interest Notice - Uvarov		19/05/23	9.26KB	Share
NSB	Change of Director's Interest Notice - Rennie		18/05/23	8.29KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	309.87KB	Share
NSB	Positive treatment effect in MS animal study	PRICE SENSITIVE	14/03/23	1.06MB	Share
NSB	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/23	1.2MB	Share
NSB	Notification of cessation of securities - NSB		06/02/23	22.16KB	Share
NSB	Investor Update Presentation		03/02/23	1.51MB	Share
NSB	Investor Update Webinar		02/02/23	157.11KB	Share
NSB	R&D Tax Incentive Refund Received	PRICE SENSITIVE	02/02/23	116.37KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	283.22KB	Share
NSB	Patent Application - Updated Announcement		15/12/22	482KB	Share
NSB	NSB files new patent	PRICE SENSITIVE	05/12/22	434.32KB	Share
NSB	Results of Meeting		24/11/22	308.92KB	Share
NSB	Chair's address to shareholders & AGM presentation		24/11/22	1.61MB	Share
NSB	Appointment of Interim CEO	PRICE SENSITIVE	23/11/22	170.98KB	Share
NSB	Executive Management Changes		15/11/22	142.13KB	Share
NSB	NSB receives R&D Advance & Overseas Finding		14/11/22	156.12KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	283.14KB	Share
NSB	Notice of Annual General Meeting		21/10/22	367.17KB	Share
NSB	Investor Update Presentation	PRICE SENSITIVE	20/09/22	1.05MB	Share
NSB	Investor Update Webinar		19/09/22	152.82KB	Share
NSB	Final Director's Interest Notice - Liddelow		16/09/22	7.06KB	Share
NSB	CEO Resignation	PRICE SENSITIVE	09/09/22	124.53KB	Share
NSB	Investor Update Webinar		07/09/22	117.82KB	Share
NSB	HREC decision to not approve Phase I Clinical Trial	PRICE SENSITIVE	07/09/22	129.59KB	Share
NSB	Corporate Governance Statement		30/08/22	212.45KB	Share
NSB	Appendix 4G		30/08/22	260.06KB	Share
NSB	NeuroScientific releases FY2022 Results	PRICE SENSITIVE	30/08/22	223.9KB	Share
NSB	2022 Annual Report and Appendix 4E	PRICE SENSITIVE	30/08/22	1.85MB	Share
NSB	R&D Tax Incentive Refund Received	PRICE SENSITIVE	17/08/22	139.55KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	292.44KB	Share
NSB	HREC Submission for Phase I Clinical Trial	PRICE SENSITIVE	12/07/22	138.38KB	Share
NSB	First Subject Recruited for Early-Phase Clinical Trial	PRICE SENSITIVE	30/06/22	142.11KB	Share
NSB	Notification of cessation of securities - NSB		27/06/22	21.74KB	Share
NSB	Company Presentation - Gold Coast Investment Showcase		22/06/22	2.33MB	Share
NSB	Clarification of Results in MS Animal Study		22/06/22	231.32KB	Share
NSB	Notification regarding unquoted securities - NSB		21/06/22	29.66KB	Share
NSB	Issue of Employee Options		21/06/22	214.24KB	Share
NSB	Positive results in MS animal study	PRICE SENSITIVE	15/06/22	147.01KB	Share
NSB	Ethics Approval Granted for Early-Phase Clinical Trial	PRICE SENSITIVE	07/06/22	140.53KB	Share
NSB	HREC Submission for early-phase Clinical Trial	PRICE SENSITIVE	11/05/22	149.59KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	284.15KB	Share
NSB	Positive safety result supports advance to clinical trials	PRICE SENSITIVE	13/04/22	144.93KB	Share
NSB	NSB Enhances Management Team		01/04/22	143.91KB	Share
NSB	Company Presentation		24/03/22	1.13MB	Share
NSB	NSB presenting at Broker Briefing Investor Webinar		23/03/22	139.34KB	Share
NSB	New data demonstrates EmtinB activity in autoimmune diseases	PRICE SENSITIVE	11/03/22	258.11KB	Share
NSB	NSB 1HY22 Key Activity Highlights	PRICE SENSITIVE	28/02/22	223.32KB	Share
NSB	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/22	885.91KB	Share
NSB	Successful completion of key studies in lead up to Phase I	PRICE SENSITIVE	08/02/22	144.51KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/22	300.57KB	Share
NSB	Positive off-target safety assessment of EmtinB	PRICE SENSITIVE	24/12/21	144.05KB	Share
NSB	Positive results in biomarker characterisation of Emtins	PRICE SENSITIVE	21/12/21	421.77KB	Share

NSB NSB Completes PRE-IND Meeting with US FDA on EmtinB
11/06/24		412.17KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
29/04/24	PRICE SENSITIVE	1.31MB	Share
NSB Notification of cessation of securities - NSB
08/04/24		12.77KB	Share
NSB Appointment of Executive Director & FDA Pre-Ind Meeting
02/04/24	PRICE SENSITIVE	416.34KB	Share
NSB NSB Receives A$2.2M Research & Development Tax Refund
20/03/24	PRICE SENSITIVE	410.52KB	Share
NSB Half Yearly Report and Accounts
27/02/24	PRICE SENSITIVE	1.01MB	Share
NSB Company Secretary Appointment/Resignation
06/02/24		115.12KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
31/01/24	PRICE SENSITIVE	311.96KB	Share
NSB Notification of cessation of securities - NSB
15/01/24		21.59KB	Share
NSB Expiry of Options
27/12/23		234.24KB	Share
NSB Final Director's Interest Notice - Rennie
07/12/23		3.33KB	Share
NSB Final Director's Interest Notice - Quantrill
05/12/23		3.43KB	Share
NSB Initial Director's Interest Notice - Keating
05/12/23		228.43KB	Share
NSB Changes to NSB Board
05/12/23		184.23KB	Share
NSB Resignation of CEO
01/12/23	PRICE SENSITIVE	178.63KB	Share
NSB Results of Meeting
30/11/23		285.36KB	Share
NSB Chair's address to shareholders & AGM presentation
30/11/23		1.63MB	Share
NSB Notice of Annual General Meeting - Withdrawal of Resolutions
27/11/23		157KB	Share
NSB Initial Director's Interest Notice - Barlow
21/11/23		226.14KB	Share
NSB Initial Director's Interest Notice - Ntoumenopoulos
21/11/23		227.89KB	Share
NSB Notification of cessation of securities - NSB
21/11/23		21.66KB	Share
NSB Addendum to Notice of Meeting
16/11/23		630.92KB	Share
NSB Further information on changes to Board
14/11/23		158.29KB	Share
NSB Changes to Board
13/11/23		169.11KB	Share
NSB Investor Update Presentation
31/10/23		2.38MB	Share
NSB Investor Update Webinar
30/10/23		150.57KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
30/10/23	PRICE SENSITIVE	357.42KB	Share
NSB Notification regarding unquoted securities - NSB
24/10/23		28.78KB	Share
NSB Proposed issue of securities - NSB
24/10/23		27.86KB	Share
NSB Notice of Annual General Meeting/Proxy Form
24/10/23		412.54KB	Share
NSB Proposed issue of securities - NSB
23/10/23		26.88KB	Share
NSB Appointment of Director - Dr Linda Friedland
18/10/23		219.75KB	Share
NSB Date of AGM & Closing Date for Director Nominations
28/09/23		165.12KB	Share
NSB Appointment of CEO
31/08/23	PRICE SENSITIVE	154.04KB	Share
NSB Appendix 4G
30/08/23		258.67KB	Share
NSB Corporate Governance Statement
30/08/23		228.23KB	Share
NSB 2023 Annual Report and Appendix 4E
25/08/23	PRICE SENSITIVE	1.6MB	Share
NSB Expiry of Performance Shares
01/08/23		153.59KB	Share
NSB Notification of cessation of securities - NSB
01/08/23		21.82KB	Share
NSB Issuance of Shares
01/08/23		159.19KB	Share
NSB Application for quotation of securities - NSB
01/08/23		24.71KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
28/07/23	PRICE SENSITIVE	339.28KB	Share
NSB Proposed issue of securities - NSB
27/07/23		24.67KB	Share
NSB Change of Director's Interest Notice - Quantrill
06/07/23		4.45KB	Share
NSB Change of Director's Interest Notice - Rennie
07/06/23		8.12KB	Share
NSB Change of Director's Interest Notice - Uvarov
25/05/23		9.25KB	Share
NSB Change of Director's Interest Notice - Rennie
25/05/23		8.11KB	Share
NSB Change of Director's Interest Notice - Uvarov
19/05/23		9.26KB	Share
NSB Change of Director's Interest Notice - Rennie
18/05/23		8.29KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	309.87KB	Share
NSB Positive treatment effect in MS animal study
14/03/23	PRICE SENSITIVE	1.06MB	Share
NSB Half Yearly Report and Accounts
28/02/23	PRICE SENSITIVE	1.2MB	Share
NSB Notification of cessation of securities - NSB
06/02/23		22.16KB	Share
NSB Investor Update Presentation
03/02/23		1.51MB	Share
NSB Investor Update Webinar
02/02/23		157.11KB	Share
NSB R&D Tax Incentive Refund Received
02/02/23	PRICE SENSITIVE	116.37KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	283.22KB	Share
NSB Patent Application - Updated Announcement
15/12/22		482KB	Share
NSB NSB files new patent
05/12/22	PRICE SENSITIVE	434.32KB	Share
NSB Results of Meeting
24/11/22		308.92KB	Share
NSB Chair's address to shareholders & AGM presentation
24/11/22		1.61MB	Share
NSB Appointment of Interim CEO
23/11/22	PRICE SENSITIVE	170.98KB	Share
NSB Executive Management Changes
15/11/22		142.13KB	Share
NSB NSB receives R&D Advance & Overseas Finding
14/11/22		156.12KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	283.14KB	Share
NSB Notice of Annual General Meeting
21/10/22		367.17KB	Share
NSB Investor Update Presentation
20/09/22	PRICE SENSITIVE	1.05MB	Share
NSB Investor Update Webinar
19/09/22		152.82KB	Share
NSB Final Director's Interest Notice - Liddelow
16/09/22		7.06KB	Share
NSB CEO Resignation
09/09/22	PRICE SENSITIVE	124.53KB	Share
NSB Investor Update Webinar
07/09/22		117.82KB	Share
NSB HREC decision to not approve Phase I Clinical Trial
07/09/22	PRICE SENSITIVE	129.59KB	Share
NSB Corporate Governance Statement
30/08/22		212.45KB	Share
NSB Appendix 4G
30/08/22		260.06KB	Share
NSB NeuroScientific releases FY2022 Results
30/08/22	PRICE SENSITIVE	223.9KB	Share
NSB 2022 Annual Report and Appendix 4E
30/08/22	PRICE SENSITIVE	1.85MB	Share
NSB R&D Tax Incentive Refund Received
17/08/22	PRICE SENSITIVE	139.55KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	292.44KB	Share
NSB HREC Submission for Phase I Clinical Trial
12/07/22	PRICE SENSITIVE	138.38KB	Share
NSB First Subject Recruited for Early-Phase Clinical Trial
30/06/22	PRICE SENSITIVE	142.11KB	Share
NSB Notification of cessation of securities - NSB
27/06/22		21.74KB	Share
NSB Company Presentation - Gold Coast Investment Showcase
22/06/22		2.33MB	Share
NSB Clarification of Results in MS Animal Study
22/06/22		231.32KB	Share
NSB Notification regarding unquoted securities - NSB
21/06/22		29.66KB	Share
NSB Issue of Employee Options
21/06/22		214.24KB	Share
NSB Positive results in MS animal study
15/06/22	PRICE SENSITIVE	147.01KB	Share
NSB Ethics Approval Granted for Early-Phase Clinical Trial
07/06/22	PRICE SENSITIVE	140.53KB	Share
NSB HREC Submission for early-phase Clinical Trial
11/05/22	PRICE SENSITIVE	149.59KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	284.15KB	Share
NSB Positive safety result supports advance to clinical trials
13/04/22	PRICE SENSITIVE	144.93KB	Share
NSB NSB Enhances Management Team
01/04/22		143.91KB	Share
NSB Company Presentation
24/03/22		1.13MB	Share
NSB NSB presenting at Broker Briefing Investor Webinar
23/03/22		139.34KB	Share
NSB New data demonstrates EmtinB activity in autoimmune diseases
11/03/22	PRICE SENSITIVE	258.11KB	Share
NSB NSB 1HY22 Key Activity Highlights
28/02/22	PRICE SENSITIVE	223.32KB	Share
NSB Half Yearly Report and Accounts
28/02/22	PRICE SENSITIVE	885.91KB	Share
NSB Successful completion of key studies in lead up to Phase I
08/02/22	PRICE SENSITIVE	144.51KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
31/01/22	PRICE SENSITIVE	300.57KB	Share
NSB Positive off-target safety assessment of EmtinB
24/12/21	PRICE SENSITIVE	144.05KB	Share
NSB Positive results in biomarker characterisation of Emtins
21/12/21	PRICE SENSITIVE	421.77KB	Share

REFRESH

1 2 3

(20min delay)
Last 3.6¢		Change -0.003(7.69%)		Mkt cap ! $5.206M

Open	High	Low	Value	Volume
3.9¢	3.9¢	3.6¢	$5.339K	142K

Buyers (Bids)

No.	Vol.	Price($)
1	17500	3.6¢

Sellers (Offers)

Price($)	Vol.	No.
3.7¢	187846	1

View Market Depth

No.	Vol.	Price($)
1	17500	0.036
3	428000	0.035
1	600000	0.033
2	633332	0.030
2	108800	0.026

Price($)	Vol.	No.
0.037	187846	1
0.039	89000	1
0.041	125000	1
0.046	25000	1
0.050	29084	2

Last trade - 14.08pm 26/06/2024 (20 minute delay)

NSB (ASX) Chart

NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available